Replies to post #180687 on Biotech Values

[DewDiligence]

What do you think of GILD's valuation now? I know you wanted to buy in the low 60's. Are you still concerned about the HIV franchise?

Yes, my opinion in #msg-100313128—that investors are underestimating the risk to GILD’s HIV franchise if TAF fails to meet expectations—still stands until the initial TAF phase-3 data are reported in 4Q14.